A cross-border French and U.S. Life Sciences team advised Mablink Bioscience in its agreement to be acquired by Eli Lilly and Company.

Mablink Bioscience is a biotechnology company developing the next generation of an emerging class of cancer drugs called antibody-drug conjugates (ADCs).

The French team was led by Anne-Charlotte Rivière, Marie Fillon and Johann Gandilhon, and included Marie-Laure Bruneel, Charlotte Muller and Louis de Chezelles.

The U.S. team was led by Steven Green, Amine Assouad and Kingsley Taft, and included Dan Karelitz, Arman Oruc, Beni Surpin, Simone Waterbury and Frank Ruofan Qin.

For more details, read the press release and coverage in BioSpace, Endpoints News and Fierce Biotech.